Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Cantor Fitzgerald
Harvard Business School
Chinese Patent Office
Citi
Covington
Medtronic
Moodys
Julphar

Generated: June 23, 2018

DrugPatentWatch Database Preview

CLOLAR Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Clolar patents expire, and when can generic versions of Clolar launch?

Clolar is a drug marketed by Genzyme and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifteen patent family members in ten countries.

The generic ingredient in CLOLAR is clofarabine. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the clofarabine profile page.
Drug patent expirations by year for CLOLAR
Pharmacology for CLOLAR
Synonyms for CLOLAR
(2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
(2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol
(2R,3R,4S,5R)-5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
(2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine
123318-82-1
2-chloro-2'-arabino-fluoro-2'-deoxyadenosine
2-Chloro-9-(2-deoxy-2-fluoro-?-D-arabinofuranosyl)-9H-purin-6-amine
2-Chloro-9-(2-Deoxy-2-Fluoro-B -D-Arabinofuranosyl)-9h-Purin-6-Amine
2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine
2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine
2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-adenine
2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine
2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine
2-Cl-2'-F-araA
318C821
3S211048
5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
762RDY0Y2H
9H-Purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-
9H-Purine-6-amine,2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-
AB00430247_06
AB00430247-03
AB00430247-04
AC-274
AC1L3OC8
ACT05522
AK163076
AKOS005063562
AKOS015919355
AN-15999
API0002064
AS-12958
BC222364
BCP0726000280
BCP9000540
BIFK0045
Bio-0121
C-18934
C1-F-Ara-A
C10H11ClFN5O3
CAFdA
CAS-123318-82-1
CC-25917
CFB
CHEBI:681569
CHEMBL1750
Cl-F-Ara-A
Cl-F-araA
Clofarabin
clofarabina
Clofarabine
Clofarabine (JAN/USAN/INN)
Clofarabine (USAN/INN)
Clofarabine [USAN:INN:BAN]
Clofarabine [USAN]
Clofarabine, >=98% (HPLC)
Clofarabine,Clolar, Evoltra
clofarabinum
Clofarex
Clolar (TN)
Clolar, Evoltra, Clofarabine
CS-0373
D03546
D0R5RR
DB00631
DR001234
DSSTox_CID_26437
DSSTox_GSID_46437
DSSTox_RID_81613
DTXSID5046437
Evoltra
Evoltra (TN)
FT-0082882
FT-0601617
GTPL6802
HMS2090A07
HY-A0005
KB-49091
KS-00000650
LS-126466
MCULE-2276059681
MFCD00871077
MLS003915615
MolPort-005-941-711
NCGC00164553-01
NCGC00164553-02
NU004666
NU006255
PubChem19116
s1218
SAR-393590
SC-22779
SCHEMBL9040
SMR002530055
SR-01000930565
SR-01000930565-3
ST24046359
Tox21_112182
Tox21_112182_1
UNII-762RDY0Y2H
W-5182
WDDPHFBMKLOVOX-AYQXTPAHSA-N
Z1557400138
ZINC3798247

US Patents and Regulatory Information for CLOLAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme CLOLAR clofarabine SOLUTION;INTRAVENOUS 021673-001 Dec 28, 2004 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for CLOLAR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 1 mg/mL, 20 mL vial ➤ Subscribe 2012-02-23

Non-Orange Book US Patents for CLOLAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,034,518 2-fluoro-9-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl) adenine nucleosides ➤ Sign Up
5,384,310 2'-fluoro-2-haloarabinoadinosines and their pharmaceutical compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for CLOLAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0038 France ➤ Sign Up PRODUCT NAME: CLOFARABINE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/334/001 DU 20060529; REGISTRATION NO/DATE AT EEC: EU/1/06/334/001 DU 20060529
C0029 France ➤ Sign Up PRODUCT NAME: CLOFARABINE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/334/001 DU 20060529; REGISTRATION NO/DATE AT EEC: EU/1/06/334/001 DU 20060529
0247 Netherlands ➤ Sign Up 300247, 20100523, EXPIRES: 20150522
C/GB06/040 United Kingdom ➤ Sign Up PRODUCT NAME: THE USE OF CLOFARABINE (2-CHLORO-9-(2-DEOXY-2-FLUORO-SS-D-ARABINOFURANOSYL)-ADENINE) FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER; REGISTERED: UK EU/1/06/334/001 20060529; UK EU/1/06/334/002 20060529; UK EU/1/06/334/003 20060529; UK EU/1/06/334/004 20060529
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Dow
McKesson
Fuji
Harvard Business School
Cerilliant
Baxter
Cipla
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.